Tag: anthracycline
Anthracycline: A type of chemotherapy drug widely used to treat breast cancer. Examples include doxorubicin and epirubicin. Anthracyclines work primarily by inhibiting DNA replication in rapidly growing cancer cells. Anthracyclines also trigger cell death by damaging cell mitochondria.
Articles
News
09/21/13
Trans fat consumption during Adriamycin chemotherapy could increase heart damage 05/30/12
Fish oil does not prevent Adriamycin-induced heart damage and might promote it 02/22/12
Selenium increases effectiveness of Taxol chemotherapy for triple negative breast cancer 02/15/12
Grapes and other foods might help protect against Adriamycin-induced heart damage 12/15/11
Kaempferol protects against Adriamycin-induced heart damage 12/07/11
Modern chemotherapy reduces breast cancer death by about a third compared to no chemotherapy 12/01/11
Herceptin plus anthracycline chemotherapy greatly increases risk of heart damage 11/09/11
Curcumin reduces breast cancer resistance to treatment with Adriamycin (doxorubicin) chemotherapy 10/26/11
Resveratrol increases effectiveness of Taxotere (docetaxel) and Adriamycin (doxorubicin) 10/09/11
Low white blood cell count as a result of chemotherapy indicates the treatment is working 10/06/11
Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer 10/03/11
Simultaneous chemotherapy plus radiation treatment reduces breast cancer recurrence 09/24/11
Caffeine may reduce the effectiveness of Adriamycin (doxorubicin) chemotherapy 09/22/11
Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer 07/11/11
Taking Celebrex might reduce the effectiveness of chemotherapy for breast cancer 04/27/11
Very low circulating coenzyme Q10 (CoQ10) linked to increased breast cancer risk 11/08/10
Response to neoadjuvant chemotherapy depends on dosage and tumor type 11/03/10
Chemotherapy resistance is accompanied by increase in number of breast cancer stem cells 07/23/10
Outcomes of breast cancer under age 35 influenced by number of positive lymph nodes 04/22/10
Coenzyme Q10 (CoQ10) might increase risk of postmenopausal breast cancer 04/14/10
Predictors of failure to respond to neoadjuvant chemotherapy
Foods
Studies
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Carvedilol for Prevention of Chemotherapy Related Cardiotoxicity Lisinopril or Carvedilol for Prevention of Trastuzumab Induced Cardiotoxicity Phenolic content, anthocyanins and antiradical capacity of diverse purple bran rice genotypes as compared to other bran colors Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature Serum IL-6 level as a predictor of response to neo-Adjuvant chemotherapy in patients of breast carcinoma Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis Quercetin protects from doxorubicin induced vascular toxicity but impairs its cytotoxic profile in breast cancer cells Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer A Systematic Review and Network Meta-analysis Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study One-tenth of patients younger than 40 years develop a permanent chemotherapy-induced ovarian function failure after receiving adjuvant anthracycline-based chemotherapy with or without taxanes The flavonoid quercetin: Possible solution for anthracycline-induced cardiotoxicity and multidrug resistance Chronic heart damage following doxorubicin treatment is alleviated by lovastatin Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis Changes in body weight during various types of chemotherapy in breast cancer patients Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007 Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis Prognostic impact of weight change during chemotherapy Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study Grape Seed and Skin Extract Protects Against Acute Chemotherapy Toxicity induced by Doxorubicin in Rat Heart Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy? Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in northeast china Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer BRCA2 deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer Adjuvant Trastuzumab in HER2-Positive Breast Cancer Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40) Chemotherapy-induced amenorrhea: Predictive markers of response to neoadjuvant chemotherapy in breast cancer Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy Response to influenza virus vaccination during chemotherapy in patients with breast cancer Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC) Pathology of late-onset anthracycline cardiomyopathy Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics The impact of young age on breast cancer outcome Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline-based neoadjuvant and adjuvant chemotherapy Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide Differential response from neoadjuvant chemotherapy across breast cancer subtypes Chemotherapeutic drug effects on spontaneous mobility and swimming endurance of mice Endurance exercise protects cardiac tissue from doxorubicin-induced proteolysis and apoptosis Docosahexaenoic acid increases doxorubicin’s cytotoxicity against breast cancer cell lines Apigenin augments the growth inhibitory effects of doxorubicin in breast cancer cells derived from African American patients Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers Aged Garlic Extract Protects against Doxorubicin-Induced Cardiotoxicity In Rats Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast? Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor Study Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids
TOP